Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elotuzumab
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Elotuzumab is a humanized IgG1 monoclonal antibody used in combination with other agents for the treatment of multiple myeloma, a cancer of plasma cells. It specifically targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), a cell surface glycoprotein highly expressed on myeloma and natural killer (NK) cells. Elotuzumab has a dual mechanism of action: it directly activates NK cells via the SLAMF7 pathway and Fc receptors, enhancing their cytotoxic activity, and it also tags myeloma cells for destruction by NK cells through antibody-dependent cellular cytotoxicity (ADCC). The drug is administered intravenously in combination with lenalidomide or pomalidomide plus dexamethasone in patients who have received prior therapies. Elotuzumab was developed by Bristol Myers Squibb and was first approved by the FDA in 2015[2][6][8].
- Brand names
- Empliciti
- Other names
- elotuzumabHuLuc63HuLuc-63HuLuc 63MuLuc63MuLuc-63MuLuc 63
02
Targets
SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on elotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elotuzumab.